Abstract | Placebo effects are beneficial effects that are attributable to the brain-mind responses to the context in which a treatment is delivered rather than to the specific actions of the drug. They are mediated by diverse processes -including learning, expectations and social cognition -and can influence various clinical and physiological outcomes related to health. Emerging neuroscience evidence implicates multiple brain systems and neurochemical mediators, including opioids and dopamine. We present an empirical review of the brain systems that are involved in placebo effects, focusing on placebo analgesia, and a conceptual framework linking these findings to the mind-brain processes that mediate them. This framework suggests that the neuropsychological processes that mediate placebo effects may be crucial for a wide array of therapeutic approaches, including many drugs.
Modern medicine has been very successful at treating many forms of disease, particularly those for which the physiological mechanisms can be identified and the pathology objectively assessed. However, it has proved difficult to treat the pain and psychological distress that are integral to many diseases 1 and to treat related dis orders such as depression, chronic pain, anxiety and fatigue. Unlike diseases in which the pathology occurs primarily in peripheral organs, pain and distress are rooted in complex brain functions. They are influenced by brain pathology, internal thoughts and brain states, and conceptions of the social and environmental context. As a result, we lack objective physiological measures for disorders that are characterized by pain and distress, and a comprehensive understanding of the brain mechanisms underlying their generation and regulation.
New inroads are being made through the multi disciplinary study of placebo effects -that is, the effects of manipulating the informational context surrounding a medical treatment. Placebos are drugs, devices or other treatments that are physically and pharmacologically inert. Placebo interventions do not, by definition, have any direct therapeutic effects on the body. However, all treatments are delivered in a context that includes social and physical cues, verbal suggestions and treatment his tory (FIG. 1) . This context is actively interpreted by the brain and can elicit expectations, memories and emotions, which in turn can influence healthrelated outcomes in the brain and body. Placebo effects are thus brain-body responses to context information that promote health and wellbeing. When brain responses to context infor mation instead promote pain, distress and disease, they are termed nocebo effects.
Understanding placebo and nocebo effects is impor tant for both clinicians and neuroscientists. Placebo responses are substantial across diverse clinical dis orders [2] [3] [4] and, in some cases, are related to objective pathology 5 and survival 6 . A large part of the overall therapeutic response to drugs [7] [8] [9] [10] , surgery 11, 12 , psycho therapy 13 and other treatments may be due to the treat ment context -and thus mechanisms shared with placebo effects -rather than the specific treatment itself. Even when attempting to understand the effects of drugs or other treatments is the primary goal, con sidering placebo effects is crucial, as drug effects occur alongside or even interact with internal psychological and brain processes 7, [14] [15] [16] [17] [18] . In some cases, individuals who show the largest drug effects also show the largest pla cebo effects 19 , which is one indicator that some drugs and placebos may share mechanisms. If so, obtaining reliable drug effects may require establishing a suitable
Context
The combination of all of the elements surrounding a given event that can be psychologically meaningful, including interpersonal dynamics, situational features owing to a place or location, memories, goals for the future and internal body or brain states. 
Emotions
Coordinated responses to biologically relevant events (such as threats and opportunities) that involve changes in multiple systems, including peripheral physiology.
Nocebo effects
Deleterious outcomes (for example, an increase in pain or an increase in negative side effects) owing to beliefs about the treatment context.
Placebo responders
Individuals who show an improvement in symptoms after receiving inert treatments (that is, placebos).
Placebo analgesia
A reduction in pain that can be attributed to the treatment context.
treatment context (for example, the right type of psycho logical or social support), and screening to remove placebo responders in clinical trials may eliminate those who most benefit from active drug treatment. For neuroscientists, placebo studies provide a way to investigate how the brain systems that process con textual information influence physiology and clinically relevant outcomes. Humans are endowed with uniquely powerful systems for representing context 20 , which help to tailor our responses to the needs of a given situation 21 . Clinical contexts in particular integrate diverse psycho logical elements (FIG. 1) , including learned associations between cues (for example, a doctor's white coat) and past positive and negative experiences, conceptual knowledge based on verbal suggestions that induce expectations about treatment outcomes, and social inter actions (for example, the patient-care provider relation ship). Placebo effects on healthrelated outcomes such as pain and affective physiology, which we focus on in this Review, share many similarities with context effects on visual perception [22] [23] [24] , memory 25 , decision making [26] [27] [28] , athletic 29 and cognitive 30 performance, and other pro cesses. Together, these studies provide a foundation for an integrated science of context processing, and stud ies of placebo may shed light on mechanisms of context effects that do not involve placebo manipulations 20, 31 .
Here, we present a brain systemsoriented view of the mechanisms underlying placebo effects. The neuro science of placebo effects is a new and rapidly evolving field that integrates diverse areas of human and animal neuro science, and complements studies of placebo effects on peripheral physiology 5 , clinical pharma cology 2 and other outcomes 20, 31 . We first briefly discuss the behavioural, clinical and physiological outcomes that are affected by placebo treatments. Then, we review neuroimaging evidence relating to the systemslevel neurobiology that underlies placebo effects; we focus primarily on pain, which has been most extensively studied. Next, we relate the resulting consensus view on the neural architecture of placebo effects in pain to brain placebo effects in depres sion, emotion and Parkinson disease (PD). Finally, we present a framework for mapping the psychological pro cesses underlying placebo effects onto brain systems and highlight several areas for further research.
Clinical and laboratory placebo effects
Placebos have been used throughout the history of medi cine to soothe the emotions of troubled patients and are still used for this purpose today 32 . It is widely believed that placebos can make people 'feel better' , but is that the extent of their clinical importance? What kinds of healthrelated outcomes can placebo treatments affect? For some, the presence of a placebo effect suggests that symptoms were not caused by 'real' or 'organic' disease. For example, patients who report pain relief after placebo treatment might be judged to be malingerers 33 . However, this inference is only valid if placebo treatments have no actual effects on pain pathophysiology or experience.
As we explain below, clinical studies have demon strated meaningful placebo effects in multiple disorders, and laboratory studies have provided evidence for pla cebo effects on healthrelevant behavioural, autonomic, endocrine and immune measures (Supplementary information S1 (table); see also REFS 5, 34) . These studies suggest that it is implausible -and perhaps unethical -to dismiss placebo responses as irrelevant to health and pathology.
Placebo effects in clinical studies. Most clinical trials are not suitable for estimating placebo effects because they lack natural history controls. However, a small subset of clinical studies with appropriate controls (FIG. 2) have demonstrated causal effects of placebo treatment on measures that are typically used as primary disease end points 35, 36 in multiple forms of chronic pain [37] [38] [39] [40] , depres sion 10, [41] [42] [43] , and can reduce disabil ity and increase quality of life over a period of months or longer 38, 43 . In some cases, particularly in cardio vascular disease 6, 50, 51 , adherence to placebo medication is associated with reduced mortality.
Placeborelated factors are also an important com ponent of standard clinical treatments that are adminis tered in hospitals and clinics, which are typically provided 'openlabel, ' with full information about drug delivery and its expected benefits. In many cases, hidden drug admin istration, which eliminates patients' treatment expecta tions, markedly reduces the effects of drugs 8, 17 ,40,52,53 and other treatments. These clinical results demonstrate the important functional improvements that are caused by the brain's interpretation of the treatment context.
Autonomic responses.
The autonomic and neuro endocrine systems are governed by the brain, includ ing 'higher' brain regions such as the prefrontal cortex (PFC) 54, 55 , and can be influenced by threatening psycho logical contexts 56 and verbal instructions 57, 58 . Several stud ies have found that placebo analgesia is associated with changes in autonomic activity [59] [60] [61] , and other studies have found evidence for diverse autonomic effects of placebo (see REFS 5, 34 and Supplementary information S1 (table) ). One such study assessed pain, autonomic responses and electroencephalography (EEG) across three levels of pla cebo 'strength' (REF. 60 ). Participants received three iden tical, inert (placebo) creams that they believed to vary in strength. A painful stimulus was then applied to the skin that was treated with the creams. During the training phase, the intensity of painful stimulation was reduced to differing degrees for the three placebo creams -not at all for the 'control' cream, slightly for the 'weak pla cebo' cream and markedly for the 'strong placebo' cream -creating differential expectations and associations of relief. In the subsequent test phase, stimulus intensity 9 cross open versus hidden administration with verum versus sham drugs, enabling researchers to assess placebo-drug interactions. c | Response conditioning designs use instructions combined with reinforcement to maximize the effectiveness of placebo treatments. In a common variant, initial verbal instructions are provided that one cream (the placebo) is an effective analgesic and another (the control) is not. Then, painful stimulation is given on both placebo-treated and control-treated skin sites. Participants are told that the stimulus intensity will be the same on both sites, but in fact it is surreptitiously reduced for the placebo-treated site, reinforcing belief in the placebo and associations with relief. During a final test phase, equivalent levels of painful stimulation are applied to both sites, and the effects of the placebo conditioning procedure are assessed. This is the most common paradigm used in neuroimaging studies; placebo and control treatments are often compared in a within-person crossover design. d | Pharmacological conditioning designs combine instructions and cues paired with active drugs during a conditioning phase, which often occurs over multiple days. Placebo effects are determined by presenting cues alone and comparing outcomes in drug-paired versus non-drug-paired groups. Response conditioning and pharmacological conditioning designs have been used in both humans and non-human animals. 
Response conditioning
The process of associating neutral stimuli with biologically meaningful outcomes, through which neutral stimuli may begin to induce anticipatory responses that are associated with the outcomes themselves.
Expectancy
A conscious, conceptual belief about the future occurrence of an event. It is a subclass of predictive processes, which may be conscious or unconscious.
was identical across skin treated with each cream, but the authors observed a graded reduction in noxious stimulusevoked skin conductance, pupil diameter and EEG N1-P2 amplitudes in proportion to the placebo 'dose' . This paradigm, which we refer to as response conditioning (FIG. 2) , experimentally manipulates associa tive learning and cognitive expectancy, and is the most popular experimental paradigm for studying placebo effects in the laboratory.
Neuroendocrine responses. Placebo treatments can also affect hormonal responses that are mediated via fore brain control of hypothalamus-pituitary-hormone sys tems (Supplementary information S1 (table)). Nocebo suggestions that a treatment will increase pain can increase peripheral cortisol levels in humans 62, 63 , an effect that is blocked by the anxiolytic benzodiazepine diazepam 62 . Strikingly, this effect was induced with ver bal instructions alone, without requiring conditioning, but in other cases associative learning might be crucial (Supplementary information S1 (table)). For example, the serotonin receptor agonist sumatriptan increases blood levels of cortisol and growth hormone. After repeated injections of sumatriptan, injections of saline alone can induce increases in the levels of both hor mones, even when suggestions induce expectations for opposing responses 65 . These hormonal effects also have parallels in animal models, which use pharmacological conditioning to associate context cues with drug effects. In rats, after repeated injections of morphine, injections of saline alone reduce pain behaviours and the levels of adrenocorticotropic hormone and corticosterone 64 . Placebos might also affect other hormone systems, including those that regulate appetite. In one study, par ticipants who drank a milkshake labelled as 'indulgent' showed reduced levels of the prohunger hormone ghrelin compared with those who drank an identical milkshake labelled as 'sensible' (REF. 66 ). These findings complement animal work on anticipatory brain regulation of appe titive hormones such as insulin, which is in many cases mediated by autonomic output to the periphery 67 .
Immune responses. The autonomic and neuroendo crine systems interact with the immune system in mul tiple ways, providing a substrate for placebo effects on immune responses. The most compelling demonstra tions of such interactions come from pharmacologi cal conditioning studies (FIG. 2) in which taste cues, such as a uniquely flavoured drink, have been paired with immunosuppressive drugs (in particular, cyclo sporin A). In both humans and rodents [68] [69] [70] , subsequent exposure to the taste cues alone suppresses peripheral immune responses, particularly T lymphocyte prolifer ation and the release of interleukin2 and interferonγ from peripheral lymphocytes. Relatively little is known about the brain mechanisms underlying such effects, although recent work suggests that they are mediated by noradrenergic sympathetic efferents 71 , require the insula and hypothalamus for their expression 72 and may be correlated with anxiety 73 , implicating forebrain control of the response.
Other recent studies suggest that placebo manipula tions may influence inflammatory responses, an aspect of immune function that is implicated in multiple aspects of health. In one study, exposure to prodrug advertising materials coupled with administration of a placebo 'anti histamine' reduced the size of skin wheal responses to an allergen challenge 74 . In another study, verbal suggestions about altitudeinduced headaches increased blood levels of prostaglandin, an important inflammatory mediator, which were reversed by administration of a placebo 213 . Notably, in this study, the suggestions were provided to one participant and were transmitted by social communi cation to others, demonstrating the power of social influ ences. Together, these studies suggest that psychological context may have more pervasive effects on physiology than is currently recognized.
Placebo effects and decision making. Despite the physi ological effects reviewed above, most demonstrations of placebo effects depend primarily on patient selfreports, mainly because selfreports are the accepted 'gold stand ard' for measuring pain and distress. One stillcommon view is that these placebo effects amount to various forms of 'decision bias' -effects on decision making -in the absence of meaningful changes in pathology or function. For example, if patients report less pain after a placebo treatment, it may be because they evaluate their experi ence relative to a different reference point 75, 76 , combine information about experience and prior expectations into their reporting decisions (a Bayesian response bias) 21 , judge that it is more costly to overreport pain than under report it (a reporting bias), or decide to simply report less pain to please the experimenter (a demand characteris tic) 214 . Thus, part of the effects of placebos on symptom reporting and behaviour undoubtedly arise from effects on decision making or other central processes that are involved in the construction of subjective experiences 77, 78 . Even without immediately affecting pathology, pla cebo effects on decision making can have profound impacts on health. They can strongly influence choices about what to eat and drink 26, 28 , how to exercise and socialize, which medications are preferable and will continue to be taken, and whether others in our envi ronment are seen as enemies or friends 79 . Such effects on decision making can compound over time to influence health in important ways.
Nonetheless, the complexity of selfreport provides a compelling rationale for studying placebo effects on objective measures that are more directly linked to specific aspects of pathology, perception and function. Direct measures of brain function, in particular, can pro vide both objective measures related to pain, suffering and brain disorders, and clues about the mechanisms by which suggestions and cues are translated into relief.
Neuroimaging evidence
Modern neuroimaging techniques, including func tional MRI (fMRI), molecular imaging of glucose, dopamine and opioid activity using positron emission tomography (PET), EEG and magnetoencephalography (MEG), offer new insights into the neural mechanisms Analgesia Pain relief, which can be caused by many factors, including medical treatments (for example, opioid analgesia), features of the treatment context (placebo analgesia) and affective states (for example, stress-induced analgesia).
Nociceptive
Receiving input from stimuli that can cause damage to tissues.
of placebo effects. Over the past 12 years, nearly 40 PET and fMRI studies of placebo effects on pain have pro vided an emerging picture of the brain systems that are involved in placebo analgesia and hyperalgesia (FIG. 3; see Supplementary information S2 (box)). These are accom panied by a small but growing literature on the effects of placebo on emotion [80] [81] [82] [83] [84] , PD 44,45,85 and depression 86, 87 , which provides converging evidence on the functions of the brain systems affected by placebo.
There are three major aims of these studies. One aim is to provide direct measures of the brain processes that give rise to pain and other clinical symptoms, providing objective targets for studies of placebo effects and other interventions. The second aim is to identify the func tional systems that are engaged by placebo treatments and thus provide information on the mechanisms by which context can influence health and wellbeing. The third aim is to identify the factors that differentiate pla cebo responders from nonresponders -or, equivalently, identify brain features that predict the magnitude of an individual's placebo response.
Placebos reduce pain-related brain responses.
Among the processes that show substantial placebo effects, pain is particularly amenable to study, because of its broad clinical relevance, experimental tractability and well studied neural circuits and mechanisms. Established 'painprocessing' systems, which receive direct or indi rect input from spinal nociceptive pathways (BOX 1) and encode the intensity of painful stimulation 88 , provide painrelated targets for tests of placebo interventions. These targets include the medial thalamus, the primary somatosensory cortex (S1) and the secondary soma tosensory cortex (S2), as well as the dorsal posterior insula (dpINS), the mid and anterior insula (aINS) and the dorsal anterior cingulate cortex (dACC) (FIG. 3) .
Placebo treatments can reduce painrelated activity in all of these regions, with the most consistent effects occurring in the dACC 53 ). Several quantitative metaanalyses on a subset of the studies that are depicted in FIG. 3 indicate that these findings are reliable across paradigms and labo ratories [103] [104] [105] . EEG and MEG studies have also shown that placebo treatments cause reductions in the amplitude of eventrelated potentials in response to painful laser stim uli 60, 77, [107] [108] [109] [110] , indicating that such treatments have an effect on rapid (~150-300 ms) sensory and cognitive responses to painful events.
These placebo effects on painrelated responses are promising. However, pain is a complex sensory experi ence that also involves affect and decision making, and it remains unclear which aspects of the pain construc tion and evaluation process are affected by which types of placebo treatments. Many of the regions that normally generate pain and show the strongest placebo effects are involved in a range of other cognitive and affective pro cesses that are distinct from pain, including basic per ceptual and decisionmaking tasks [111] [112] [113] [114] and emotional responses that are independent of pain 115 . The regions most directly linked to nociceptive processing 116 and most specific to pain 112 are the dpINS and S2. Although placebo treatments have been shown to affect these regions 61, 101 , such effects are not consistently identified in metaanalyses 103 , pointing to variability across studies and individuals. Some placebo paradigms -for exam ple, those that involve extended conditioning or particu larly powerful manipulations of belief -may have more
Box 1 | Converging circuitry and common mechanisms for analgesia and affective states
Interactions among the prefrontal cortex (PFC), the forebrain and the periaqueductal grey (PAG)-rostroventral medulla (RVM)-spinal cord axis underlie multiple forms of analgesia, including placebo effects. These circuits are also integral to generating affective and motivational states. Likewise, the neurochemical systems implicated in placebo analgesia 2 -including opioid (OP), dopamine (DA), serotonin, cholecystokinin (CCK) and oxytocin systems -have diverse roles in motivated behaviour beyond pain. Seen in this light, placebo-based modulation of pain is one example of a broader pattern of regulation of affect, perception and behaviour by cognitive and motivational context.
The context-based modulation of pain and motivation is supported by convergence between 'bottom-up' sensory processes and 'top-down' context at multiple levels of the neuraxis. Nociceptive afferents from the spinal cord project to brainstem regions (including the PAG and RVM), thalamic nuclei and forebrain regions (including the hypothalamus (HYP), amygdala (AMY) and ventromedial PFC (vmPFC)) 194, 195 (see the figure, part a) . These regions also receive monosynaptic inputs from the vmPFC 55, 196 . Thus, brainstem and forebrain centres integrate input from the 'lowest' and 'highest' levels of the neuraxis, providing multiple convergence zones for sensory input and contextual information.
The PAG-RVM-spinal cord axis is important for many forms of pro-and anti-nociception in non-human animals, paralleling involvement in human placebo and nocebo effects, including forms of 'stress' analgesia present even in decerebrate animals 197 . This axis is, in turn, governed by evolutionarily newer forebrain neural and neurochemical systems, which interact with the PAG-RVM pathway to mediate diverse types of pain-modulatory effects (see the figure, part b). For example, in intact animals, both footshock-induced analgesia and morphine analgesia require OP-DA interactions in the ventral tegmental area (VTA) and nucleus accumbens (NAc) 198, 199 , which influence 'pain off' spinal projection neurons in the RVM. Threat-or fear-conditioned analgesia relies on the release of OPs 146, 200 and cannabinoids (CBs) 201 in the AMY and PAG, respectively, which also activates RVM 'pain off' neurons. Analgesia related to noxious stimulation 202 and massage-like touch 203 depends on oxytocin (labelled 'Oxy') release from hypothalamic projections to the PAG and subsequent OP release 204 . The PAG-RVM circuit also mediates some kinds of pro-nociceptive actions. CCK antagonizes OPs in this system 205 and may underlie nocebo hyperalgesia 62 , OP hyperalgesia 215 and safety signal-mediated hyperalgesia 206 . Other motivational states related to hypothalamic and forebrain circuits -including food pursuit 207 , micturition, and social conflict and defeat 208, 209 -can also influence nociception, providing additional clues that pain control circuits evolved as part of an integrated system governing adaptive behaviour. lOFC, lateral orbitofrontal cortex; PBN, parabrachial nucleus. profound effects on the sensory transmission of pain, whereas others may primarily affect emotion and deci sion making. Advances in neuroimaging methods, which are beginning to identify more precise signatures for pain and other affective processes
, will permit stronger tests of which placebo paradigms influence painspecific versus more general affective processes.
Placebos engage endogenous pain modulation circuitry. A wealth of animal research has established numerous brain systems for the modulation of pain at multiple levels of the neuraxis, from the spinal cord up to the PFC [117] [118] [119] [120] 
.
One important set of systems are descending pain modulation systems, which comprise projections from the brain stem to the spinal cord that can facilitate or reduce spinal nociceptive responses (for example, see REF. 120 ). These systems involve multiple pathways and neurochemical sys tems, including opioids, serotonin, dopamine, noradren aline, oxytocin, cholecystokinin and neurokinin 1 (for a review, see REF.
2). Particularly important among them is a central opioidergic pathway from the midbrain periaq ueductal grey (PAG) through the rostroventral medulla (RVM) to the spinal cord. The PAG receives direct projec tions from the ventromedial PFC (vmPFC), ventrolateral PFC (vlPFC), amygdala, nucleus accumbens (NAc) and hypothalamus 55, 121, 122 , permitting prefrontal cortical and limbic control over both afferent input and central pain circuitry. Beyond pain, PAG circuitry is critical for several other motivated behaviours 122, 123 and is activated during human emotional responses [124] [125] [126] .
Beginning with the work of Levine, Gordon and Fields 127 , multiple studies have shown that placebo anal gesia can be blocked by the opioid antagonist naloxone (for example, see REF. 128 ), implicating opioidergic pathways in placebo effects. Neuroimaging studies that examine fMRI and opioid activity in brain areas rich in opioids, particularly the PAG and RVM, have comple mented and expanded on this work. PET studies have found placeboinduced increases in μopioid activity (measured as decreases in binding of 11 Ccarfentanil) in the PAG [129] [130] [131] . Consistent placeboinduced increases in blood oxygenation leveldependent (BOLD) activity in the PAG during both the anticipation 90,94 and experi ence 61, 103 of pain have been observed in fMRI studies, and several studies have shown that placeboinduced increases in PAG BOLD activity are correlated with the strength of analgesia 61, 90, 132 (although not always; see REF. 53 ). Placebos have also been found to increase activity in the vicinity of the RVM 61 . Importantly, the placebo effects on PAG and RVM activation, as well as on painrelated brain activity, can be reversed by nalox one 61 . These findings directly implicate endogenous opioid responses in the brainstem as a mechanism of placebo analgesia.
In rodents and primates, activation of the endogenous opioid system can in some cases reduce the transmis sion of nociceptive signals in the dorsal horn of the spi nal cord, which prevents them from reaching the brain. A small set of recent studies suggest that placebos can also engage this type of descending modulatory control.
Box 2 | Brain-based biomarkers for pain and affect
To study pain, depression and other conditions that affect the brain, we must first identify biomarkers -observable physiological measures -for the processes that give rise to them 174 . For example, functional MRI (fMRI) responses during pain in the dorsal anterior cingulate cortex (dACC) and anterior insula (aINS) are commonly used as markers for pain. When activity in these regions is affected by placebo, or other treatments, it is assumed that the treatment affects pain-related neural activity in these areas, and thus it is inferred that the placebo affects 'pain processing'.
At first, this seems reasonable, as the dACC and aINS contain neurons that encode nociceptive information 210 . However, there are two central problems with this inference. First, each 'voxel' in a typical neuroimaging study contains approximately 5.5 million neurons 211 . Neurons in the dACC and other 'pain-processing' regions encode diverse forms of information, some unrelated to pain. The examination of fMRI activity across thousands of studies has revealed that the dACC and aINS are among the most frequently activated areas in the brain, regardless of the psychological task [111] [112] [113] [114] . Second, pain is likely to be encoded in a distributed circuit, and it is unclear whether measures in individual brain regions -whether fMRI or cellular -are sufficient to capture the mechanisms underlying pain experience.
For a pattern of brain activity to be useful as a biomarker for pain, the pattern must be sensitive and specific to pain. These criteria, and other related metrics that can be derived from them ('precision' and 'recall', and positive and negative predictive value), are the bedrock of any diagnostic test. Sensitive measures of pain respond reliably, with large effect sizes that track the intensity of pain, and thus show a high probability of being present when pain is experienced. Specific measures respond only to pain and have a low probability of being present when pain is not present.
Recently, it has been demonstrated that distributed patterns of fMRI activity can be identified that are both sensitive and specific to pain. One pattern, termed the 'neurologic pain signature' (NPS) 174 , can be applied to individual participants to make accurate predictions about pain intensity and has been validated across several studies. Although it is activated by painful events and reduced by opioid treatment, it does not respond to other emotionally salient events 115, 174 , demonstrating specificity to pain. Markers such as the NPS provide more precise targets for a new generation of placebo studies. Thus far, there are few tests of placebo effects on such markers; but, in one study, a placebo manipulation that affected reported pain had no effect on responses in the NPS 174 . In another, cognitively 'rethinking' pain, a psychological intervention related to placebo, strongly affected pain reports but also had no effect on the NPS 106 . Rather, the effects of cognitive regulation were mediated by brain signals in an independent pathway connecting the ventromedial prefrontal cortex and nucleus accumbens. These findings suggest that the NPS was only influenced in a subset of studies in which pain reports were affected. Whereas placebos may affect nociception in fundamental ways in some cases, they may independently affect the evaluation and functional consequences of pain in others; such effects may be mediated by separate brain pathways.
Placebo treatments can reduce spinal responses to pain ful stimuli 133 and reduce secondary hyperalgesia around a site of painful stimulation 134 , which is thought to be spinally mediated in many cases. Conversely, nocebo suggestions of hyperalgesia can increase spinal fMRI responses to painful events 59 and reverse the effects of normally analgesic procedures on spinal nociceptive reflexes 135 . Although laterstage modulation of pain in the cerebrum is still likely to contribute to many types of placebo effects 77, 78 , these findings strongly suggest that placebos can influence spinal nociception and modulate ascending painrelated signals.
In addition to the evidence on descending modu latory systems, there is now substantial evidence that placebo treatments engage multiple systems in the PFC, NAc and amygdala, and influence the functional con nectivity between them. Such engagement may include both changes in 'mindset' , perhaps reflected in changes in tonic metabolic activity (for example, see REF , and a recent study using diffusion tensor imag ing found that strong placebo responses were associated with greater integrity in the white matter tracts that con nect both the dlPFC and the vmPFC with the PAG 142 . Placebo treatment also strengthens functional connec tivity between the vmPFC and PAG, which can be meas ured in terms of correlations in fMRI time series 61, 139 , and increases the correlation between the dACC and PAG 129 in levels of opioid binding, which is consistent with central opioid release. Placeboinduced vmPFC-PAG connectivity is also reversible by naloxone 61 , further implicating opioid mechanisms. All of these findings are consistent with placeboinduced central opioid release under the control of the PFC.
These findings have parallels in animal models that corroborate the importance of PFC-PAG connectivity in pain control. Stimulation of the lateral orbital PFC in rats can reduce nociceptive responses, and these effects require opioid release in the PAG 143 . Other work in rodents indicates that lateral PFC-brainstem projections may mediate some of the analgesic effects of thalamic stimulation 144 . These findings imply that projections from the PFC to the PAG might be important for many forms of pain control beyond placebo analgesia
The amygdala, NAc and ventral striatum (VS) are also closely connected to the medial PFC (for example, see REF. 122 ). Across studies, placebo analgesic treatments reliably reduce activity in the amygdala and increase activity in the NAc-VS 103 (as these nearby regions are dif ficult to distinguish reliably with fMRI, we refer to them together), although they are discussed less frequently than the cortical regions discussed above.
In the amygdala, placebo treatments increase endo genous opioid responses (that is, they reduce opioid receptor binding), as observed by PET 129 , and reduce fMRI activity during pain 16, 17, 61 , an effect that can be blocked by naloxone 61 . Larger placeboinduced reduc tions in BOLD fMRI correlate with stronger placebo induced analgesia 53, 100 . The amygdala has a central role in encoding and maintaining sensory associations with potential threat (for example, see REF. 145 ), and placebo treatments may reduce the threat value and/or salience of pain cues. Opioid signalling in the amygdala, and pro jections to the PAG-RVM system, are also crucial for pain inhibition in animal models of threatconditioned analgesia 146 . Together, these studies suggest that amygdala circuitry is important for both placebo and other analge sic effects that arise from competing motivational states. Further work is needed to determine whether placebo and threatrelated analgesia are mediated by opposing or similar influences on amygdala circuits.
A different pattern of placebo effects is found in the NAc-VS: placebo treatments cause increases in NAc-VS fMRI responses during pain 53, 96, 103 and in opioid [129] [130] [131] and dopamine 130 activity as measured by PET. Dopamine and fMRI activity increases in the NAc-VS have been strongly linked with appetitive learning 147 , desire 148 , social rewards 149 and motivational engagement 150, 151 , as well as positive shifts in emotion 152 and pain reduc tion induced by selfregulation 106 . The NAc may also have a particularly important role in the motivational and behavioural aspects of pain 119, 153, 154 . For example, in animal models, chronic inflammation and nerve injury induce signs of depression and fatigue (for example, reduced reward seeking) that are accompa nied by structural changes in the NAc 154 and vmPFC 155 . Strikingly, blocking the neuropeptide galanin in the NAc reversed both these structural and motivational effects 154 . In humans, fMRImeasured functional con nectivity between the vmPFC and the NAc-VS predicts the development of chronic back pain 1 year later 156 , implicating this circuit in longterm painrelated behav iour. Thus, findings of placebo effects in the NAc-VS may have important consequences on painrelated behaviour and other motivational processes.
Pre-cognitive associations
Links between events and/or objects that exist outside conscious awareness. These links are generally created through conditioning procedures or innate (evolutionarily afforded) associations.
Conceptual processes
Processes that depend on an interpretation of the situational context and its relationship to prior information (for example, memories and rules), including interoceptive cues from the body, and which can be updated in response to verbally presented or symbolic information.
The NAc-VS may also be important for predicting individual differences in the strength of placebo effects (that is, identifying placebo responders). Strong placebo analgesic responses are predicted by NAc-VS structure and function, including stronger placeborelated opi oid 129,131 and fMRI activity 17, 53 responses during pain, increased grey matter volume 157 and stronger fMRI responses in a rewardpursuit task unrelated to pain 158 . NAc-VS grey matter volume and placeboinduced opioid responses are also positively correlated with personality measures related to optimism, reward seeking and resil ience 132, 157 . These findings suggest that interindividual differences in NAc-VS structure and function may provide clues as to why some individuals are placebo responders and others are not. In addition, activation of the NAc-VS during pain predicts the magnitude of opioid analgesia 159 , providing support for the notion that brain reward circuitry is implicated in both placebo effects and other forms of pain modulation.
Beyond pain: placebo effects on motivational systems. Although placebo effects on brain function have been most extensively investigated in the context of pain, a select group of studies has begun to show that many of the systems discussed above are involved in placebo effects in other areas too, including emotion 80, [82] [83] [84] 160 , motor performance 45, 161 and learning 85 in PD, and depression 86, 87 . The earliest studies of the brain mechanisms under lying placebo effects in domains other than pain examined placebo effects in PD and depression. One landmark PET study of dopamine activity 45 found that placebo administration increased striatal dopamine binding in patients with PD, particularly in those who perceived an improvement in clinical status with placebo treatment. Subsequent studies found that individuals with PD who showed placeboinduced improved motor performance also showed placeboinduced increases in subthalamic nucleus firing 161 , that PD patients' thera peutic expectations are correlated with placeboinduced striatal dopamine release 44 and that placebos mimic the effects of dopamine drugs on rewardlearning signals in the striatum and vmPFC 85 . An adjacent region of the vmPFC, in the subgenual cingulate cortex, also showed placeborelated reductions in glucose metabolism in depression 86 . This region is thought to be a critical hub for depression 162 , and subgenual cingulate cortex stimulation has shown great promise as an interven tion for treatmentresistant depression 163 . These studies provide promising links between the effects of placebo treatments on medial prefrontal-striatal circuitry and improvements in psychopathology.
Studies of placebo effects on emotion processing also dovetail with findings relating to placebomediated anal gesia. In one study, a placebo 'anxiolytic' reduced both the unpleasantness of negative images and amygdalar and extrastriate cortical responses to the images 80 . These effects were also associated with increased activity in the lateral OFC and dACC, regions that are also implicated in placebo analgesia 164 . In another series of studies, treat ment with a placebo 'antinausea' pill reduced ratings of disgust in response to negative images 83, 84 . These effects were accompanied by reductions in insular and visual cortical activation and reduced functional connectivity between the insula and both the amygdala and visual cortices. Finally, a placebo nasal spray, paired with sug gestions of increased touch pleasantness and reduced pain, produced similar increases in vmPFC, NAc-VS, amygdala and PAG activity during both pleasant and painful touch 165 . However, somatosensory cortical activ ity increased during pleasant touch and decreased dur ing pain. Thus, placebo effects on pleasant touch may engage similar forebrain motivational circuitry but have opposite effects on somatosensory processes.
Together, these studies elucidate the neural circuitry underlying placebo effects. Converging evidence indi cates that placebo treatments engage prefrontal-sub cortical systems that are involved in valuation, emotion and expectation. These systems can affect both sensory aspects of pain, via descending brainstem and spinal modulation, and functional and affective aspects of pain as well as other emotional and motivational pro cesses, via interactions with the striatum and amygdala. Placebo effects in cortical-brainstem systems depend in part on opioid involvement: placebos can cause cen tral opioid release in the cortex, NAc-VS and PAG 129 , and placebo effects on both painrelated increases and decreases in fMRI activity are blocked by naloxone 61 . However, a range of other neurochemicals, including dopamine, cholecystokinin and oxytocin, are also likely to be involved in the placebo response 2
; for exam ple, one recent study found that intranasal oxytocin enhanced placebo analgesia 166 . Studies of placebo can also be viewed in conjunction with other forms of affec tive and perceptual regulation by context and expectancy, such as valuebased modulation of hedonic responses 28 and cuebased modulation of visual and auditory percep tion 23, 24, 167, 168 , although full consideration of all of these studies is beyond the scope of this Review.
New frontiers in placebo research
The emerging neuroscience of placebo effects suggests a remarkable consistency in the brain systems engaged across studies and healthrelated domains, including pain, PD, depression and emotion. However, this appar ent consistency belies a deep complexity, the untangling of which has barely begun. Placebo studies widely dif fer in both the outcomes that are assessed and the likely psychological processes involved. As Benedetti writes 2 : "There is not one placebo effect, but many." To move forward, we must jointly consider the variety of psycho logical mechanisms that are involved in placebo effects and how they relate to brain systems.
In this section, we provide a framework that includes three types of psychological antecedents that give rise to placebo effects -pre-cognitive associations, conceptual processes (for example, expectancies) and affective or motivational states -with different brain substrates. These antecedents give rise to placebo effects on three kinds of outcomes: diseaserelated symptoms (for exam ple, pain), physiological signs and other behaviours. Using this framework as a platform, we explore several Schema A conceptual, 'situational' pattern -inferred from a combination of sensory cues, internal motivation, interoceptive information and thoughts -that can activate scripts that guide behaviour based on the nature of the situation rather than any single cue.
frontiers and areas of new opportunity. The first fron tier concerns differences across types of outcomes. We ask whether placebo effects on different outcomes really share common mechanisms, and what functional roles the regions consistently activated by placebos, such as the PFC, might have. The second frontier concerns the requisite antecedents for placebo effects. We explore the hypothesis that both conceptual and learning processes are required for many kinds of placebo effects and discuss how these may relate to brain systems. Finally, although in many cases placebo effects require learning -driven by experienced benefit after receiving the placebo -in some cases placebo effects persist despite contrary expe riences. We ask what the mechanisms underlying such 'selfreinforcing' placebo effects might be.
Mapping psychological mechanisms onto brain systems.
The principal building blocks of laboratory placebo para digms include three elements: presentation of sensory cues associated with positive outcomes (for example, pain relief) or negative outcomes (for example, shock) through classical conditioning; verbal suggestions designed to induce expectations of therapeutic improvement or symp tom exacerbation; and the delivery of placebo manipula tions in a context that includes both rich associative cues (for example, a hospital setting) and information about the interpersonal relationship (for example, knowledge that treatment is provided by an expert caregiver). These 'treatments' can elicit a range of therapeutically relevant internal brain processes (FIG. 4a) . One useful distinction is between processes that are precognitive -that is, inde pendent of what a person expects or believes -or con ceptual -that is, dependent on thoughts, expectations and memories. Conditioned cues can elicit precognitive associations, which are simple forms of memory that are supported by neuroplastic changes in specific circuits throughout the brain and the spinal cord. These associa tions can trigger multiple types of responses, depending on the nature of the circuit and its location in the brain, including autonomic and neuroendocrine responses, Nature Reviews | Neuroscience , reported experiences (symptoms) and behaviour. These outcomes are influenced in various ways by the two primary components of the treatment context: conceptual processes and pre-cognitive associations. Conceptual processes can influence expectations, appraisals and memories, which can directly influence emotional states, reported decisions and behaviour. Pre-cognitive associations influence physiological processes outside conscious control, which can in turn influence emotion, motivation and affective states as well as outcome measures. Thus, some types of placebo effects may be mediated by affective and motivational states, whereas others may be independent of such states, depending on the nature of the context and the outcome. b | Conceptual processes have been difficult to define and measure precisely in the brain, because they depend on the integration of information associated with multiple systems into an overall schema, or conceptualization of the situation and its implications for well-being, which guides the meaning or significance of events. The ingredients of such 'meaning responses', which are thought to be critical for placebo effects 212 , include inferences about social information (dorsomedial prefrontal cortex (dmPFC)), interoceptive assessments of one's body state (insula), expectancies (lateral orbitofrontal cortex (lOFC)) and autobiographical memories and place context information (hippocampus (Hipp)). The ventromedial PFC (vmPFC) is positioned to integrate these elements into a coherent schema that informs and is informed by responses at other processing levels 170 , including brainstem and subcortical centres that regulate sensory, autonomic and neuroendocrine responses. AMY, amygdala; HYP, hypothalamus; NAc, nucleus accumbens; PAG, periaqueductal grey; RVM, rostroventral medulla.
emotions and motivated behaviours. Verbal suggestions and background beliefs about the treatment context can engage multiple conceptual processes: expectations of specific outcomes, appraisals of the significance of both symptoms and treatment, and explicit memories of prior experiences. If they are sufficiently relevant for survival and wellbeing, both precognitive associations and conceptual thought can induce emotional and motiva tional states, which may underlie some forms of placebo effects 158, 169 . These mediating processes differentially influ ence different classes of observable outcomes, including reported experiences (for example, symptoms), behaviour and physiology.
Although placebo effects may engage similar classes of processes (for example, expectancies) across disorders and outcomes, resulting in substantial convergence in the neu robiological systems typically involved, no single process or system mediates all types of placebo effects. A challenge for the next generation of placebo studies will be to specify which psychological antecedents produce placebo effects on specific brain systems and outcomes.
Different mechanisms for different outcomes?
Although placebo effects can encompass symptom reports, physio logical signs and other behaviours, it is far from clear which brain pathways are essential for the effects on each type of outcome. Most placebo studies have exam ined symptoms such as pain as a behavioural end point, and brain correlates of the strength of placebo effects 104 are thus largely limited to the correlates of changes in symptoms. Direct comparisons of the brain mecha nisms underlying placebo effects across outcomes (for example, pain, PD symptoms and emotion) and types of outcomes (for example, symptoms and physiology) have seldom been carried out.
It is thus still unclear whether brain regions such as the PFC and NAc, which seem to be consistently associ ated with placebo effects in pain, dopaminergic systems and beyond, are really engaged in the same way across disorders. The vmPFC and other prefrontal areas are critical hubs for conceptual meaningmaking processes 170 (FIG. 4b) , making them natural candidates for common antecedents of placebo effects across outcomes. However, very few studies make direct comparisons across out comes. A pair of studies 82, 160 have provided another kind of evidence on shared mechanisms: they exam ined whether placebo suggestions about one outcome (pain) influence another (emotion). A placebo 'analge sic' reduced the unpleasantness of negative images and the magnitude of the P2-N2 complex, an EEG marker of early visual processing 82 . Subsequent fMRI 160 scans revealed that placebo administration reduced amygdala and insula responses to unpleasant images and increased activation in the subgenual ACC, a part of the vmPFC zone. Thus, this provides some initial evidence that pla cebos engage brain mechanisms in a way that transfers across outcomes.
A related question is which aspects of placeboinduced changes in fronto-striatal-brainstem systems are related to effects on pathophysiology, internal states that drive behaviour in meaningful ways or decision bias -effects of conceptual processes on symptoms, without concomi tant effects on behaviour and pathophysiology. For some researchers, vmPFC activation might be taken as an indi cator of decision bias. Responses of the vmPFC during the viewing of desirable items predict how much a par ticipant is willing to pay for the item 171 and are sensitive to beliefs about the object (for example, the price of a bot tle of wine 26 ) and one's goals (for example, dieting goals when viewing food items 172 ). However, vmPFC activa tion in placebo studies might also indicate effects of more enduring significance, in two ways. If conceptual processes affect health behaviours (for example, choices about food, exercise and social behaviour) 150 , they can have a lasting, longterm impact on disease. For example, smokers who showed larger vmPFC responses during viewing of anti smoking advertisements were more likely to subsequently attempt to quit smoking, and vmPFC responses were more predictive than standard focusgroup responses to the advertisments 173 . Despite their prominent role in decision making, vmPFC responses in placebo studies may also be related to influences on pathophysiology, including noci ception and physiological responses
. The vmPFC projects directly to the PAG, hypothalamus and other autonomic centres 54 , and its connections with the PAG mediate some kinds of conceptually driven autonomic responses, such as social evaluative threat 56 . Thus, one may ask, which potential outcomes is vmPFC (or lateral PFC, or NAc) activity related to in any given placebo study?
Two new research directions may provide impor tant clues. The first is examination of PFC-brainstem connectivity. Enhanced vmPFC-PAG connectivity in placebo studies suggests descending regulation of pain physiology or autonomic or neuroendocrine responses. In future studies, it may be possible to separate patterns of prefrontal activity that differentially relate to brainstem or spinal cord responses and measures of pathophysiology, symptom reports independent of pathophysiology and longterm placeboinduced changes in behaviour.
The second direction is the development of brain measures that provide new markers of neuropatho physiology for mental health and neurological disorders
. In pain, these include brain indices of early noci ception 59, 133 and central painconstruction processes 174 . In PD, they include measures of dopamine activity 45 and dopaminelinked brain processes 85 . The brain correlates of placebo effects on these new measures may be similar to or different from those related to selfreported out comes. For example, in one recent study of placebo anal gesia, the brain patterns predictive of the magnitude of placebo effects on pain reports versus painrelated brain responses were distinct, although frontal cortical systems were involved in both 100 .
Understanding the role of conceptual processes. Another frontier is understanding which types of placebo mecha nisms -including precognitive associations, con ceptual thought and emotional states -are required to elicit changes in brain processes that are relevant to health and disease. Nearly all of the studies that pro duced convincing placeboinduced decreases in pain related brain responses and increases in activity in Attributions Inferred causality; the process of assigning an observed effect (for example, a symptom) to an underlying cause or mechanism.
pain and emotionmodulatory circuitry (FIG. 3) utilized the response conditioning procedure, which involves both creating expectations via verbal suggestions and reinforcing those expectations through classical condi tioning. Although conditioning is frequently thought of as creating 'hardwired' associations in neural circuits, decades of empirical work suggests that in many cases conditioned responses in humans and rodents alike depend on the information value of the cue -that is, the expected outcome -rather than obligatory, precog nitive associations [175] [176] [177] [178] . Thus, it is still unknown whether placeboinduced neuro modulation is created by the belief in the placebo, expectations of positive outcomes or specific associations learned through reinforcement.
Conditioning and expectancy have traditionally been offered as competing alternatives for placebo effects [179] [180] [181] [182] . However, there is growing evidence that a combination of precognitive associations and conceptual processes may be required. Placebo effects elicited by verbal sug gestions alone have been reported, including some effects on physiology (Supplementary information S1 (table)), but on the whole these effects are weak and inconsistent across studies. The most compelling example -that is, the induction of cortisol release by suggestions of strong upcoming pain -may have worked by eliciting strong emotional responses. Perhaps surprisingly, reinforcement alone without verbal instructions does not often yield robust placebo effects either; adding verbal instructions to reinforcement alone typically produces much stronger effects 109, 183, 184 . In addition, conditioned placebo effects can often be reversed by verbal suggestions. For example, autonomic responses can be conditioned in humans and animals by pairing previously neutral sensory cues (for example, lights) with shocks. Such responses can be reversed in a single trial by instructing participants that the lightshock contingency is no longer in effect 58 (for a review of related paradigms, see REF. 178 ). In a minority of cases, placebo effects may be insensitive to beliefs: for example, in conditioned immunosuppression 185 and some forms of pharmacological conditioning 65, 186 . However, even in these cases, verbal suggestions may support condition ing during learning; thus, having the right belief may still support the formation of placebo effects in these systems.
One way in which conceptual processes may interact with experiences (that is, reinforcement) is by guiding attributions -beliefs about the nature of the events that caused pain relief or other therapeutic outcomes. For example, imagine that you take a pill to relieve a head ache and an hour later the headache disappears. You must decide whether to attribute the relief you feel to the pill or the natural course of events. Attributions such as this probably guide what we learn from experiencing out comes with multiple potential causes in many situations. Several placebo studies 184, 187, 188 have found that response conditioning -pairing a cream with reductions in the intensity of painful stimuli -resulted in placebo analge sia (and reduced EEG potentials 188 ) during a later test, but only as long as participants were not aware of the reduc tion and believed that the stimuli were just as intense on the placebotreated site. When participants were informed that the stimulus intensity would be reduced, no placebo analgesia occurred, although the condition ing procedure was otherwise identical. Conditioned analgesia required both the experience of reduced symp toms and the attribution of efficacy to the cream. Thus, another potential function of prefrontal cortical activa tion after placebo treatment is to guide attributions of efficacy; if they favour the treatment, learned placebo may be strengthened in other systems, including the amygdala, the NAc-VS and the brainstem.
Attribution may be important in appetitive learning as well as in pain: a positive outcome following what one believes is a good choice reinforces the choice, but a posi tive outcome following a bad choice may be attributed to luck. Several recent studies suggest that this type of attribution shapes appetitive learning: participants learn the reward values of cues faster when reward feedback is compatible with prior beliefs induced by verbal sugges tion [189] [190] [191] . These studies imply that dopaminergic reward learning is enhanced by prior beliefs in the reward value of the cues. All of these effects are consistent with the idea that suggestions influence the creditassignment process during learning and suggest that conditioned placebo responses in the NAc-VS, and possibly other regions, may depend on attribution of benefit to the placebo.
Self-reinforcing placebo effects?
One of the mysteries sur rounding placebo effects is that they can sometimes be stable or even increase in magnitude over time 184, 192, 193 . But if placebo effects are a conditioning phenomenon that is learned during a training phase, then they should extinguish during subsequent testing, when symptoms (such as experienced pain) are higher than expected in placebo conditions. Although it remains largely unex plored at the brain level, two of the mechanisms dis cussed here might be particularly important for creating selfreinforcing placebo effects that last through time. First, if experienced benefits are attributed to a treatment when they match prior beliefs (for example, when pain experience is low) but not otherwise (for example, when pain is high), then disconfirmatory experiences will be discarded and belief in the placebo will persist. Second, if placebo treatments have deep effects on the sensory processes that give rise to symptoms (for example, spinal responses to painful events), belief in the placebo will not be disconfirmed because the ascending noxious input will be dampened. These conditions allow placebo effects to become selffulfilling prophecies. Much work remains to test these mechanisms and the brain processes that sup port them, but doing so could help us to understand and ultimately harness the power of belief for creating positive, longterm change.
Conclusions
A substantial part of the therapeutic benefit patients expe rience when undergoing medical treatment is caused by their brain's response to the treatment context. Laboratory investigations of placebo effects provide a way of exam ining the brain mechanisms underlying these effects. Consistent findings across studies include reduced activity in brain areas associated with pain and negative emotion, and increased activity in fronto-striatal-brainstem cir cuits. In most cases, the creation of robust placebo effects across disorders and outcomes seems to require appropri ate conceptual beliefs -maintained in prefrontal cortical networks -that are supported by experiencedependent learning in striatal and brainstem circuits. However, the critical ingredients for eliciting placebo effects, at both the psychological and brain level, are just beginning to be understood. These ingredients may differ substantially depending on whether the outcomes are symptoms, behaviours or changes in physiology. A better under standing of the neuroscience of placebo could yield rich benefits for both neuroscience and human health.
